It is a feverish hunt for ways to treat one of the deadliest infections the world has known since the 1918 Spanish flu. As millions more are infected by covid-19, researchers are scrambling to come up with a range of items to cope with the pandemic—from easy-to-use diagnostic kits and medicines to the holy grail of them all: a vaccine against the severe acute respiratory syndrome (sars) coronavirus-2, which causes the covid-19 disease.
Vaccines, however, are a long way off even though over a hundred pharma companies, research institutions, and global collaborations have been set up to find the magic bullet (see ‘Hope or hype?’ on p46) to halt the pandemic. The vaccine hunters may be attracting big money and headlines, but as much of the research attention is focussed on existing therapies to help patients—especially those who become critically ill—to fight the virus. These endeavors are as fascinating as they are varied, drawing in systems biologists, Big Pharma, universities, start-ups, and a host of others in an effort to stop sars-cov-2 from reaping a deadly harvest.
Since every virus is different, new drugs have to be developed to fight diseases. But this takes time—of several years—and requires humungous amounts of money. Covid-19 does not allow us that kind of luxury; it spreads extraordinarily fast and that is the danger that hangs over the world, although compared to other viruses such as Ebola and Zika it is not so deadly. So readily available drugs are under the scanner in laboratories across the world where researchers are narrowing their search to find medicines that work best against the virus. Repurposing is the new strategy.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
Trade On Emissions
EU's Carbon Border Adjustment Mechanism, a tariff on imports, is designed to protect European industries in the guise of climate action.
'The project will facilitate physical and cultural decimation of indigenous people'
The Great Nicobar Project has all the hallmarks of a disaster-seismic, ecological, human. Why did it get the go-ahead?
TASTE IT RED
Popularity of Karnataka's red jackfruit shows how biodiversity can be conserved by ensuring that communities benefit from it
MANY MYTHS OF CHIPKO
Misconceptions about the Chipko movement have overshadowed its true objectives.
The politics and economics of mpox
Africa's mpox epidemic stems from delayed responses, neglect of its health risks and the stark vaccine apartheid
Emerging risks
Even as the world gets set to eliminate substances threatening the ozone layer, climate change and space advancement pose new challenges.
JOINING THE CARBON CLUB
India's carbon market will soon be a reality, but will it fulfil its aim of reducing emissions? A report by PARTH KUMAR and MANAS AGRAWAL
Turn a new leaf
Scientists join hands to predict climate future of India's tropical forests
Festering troubles
The Democratic Republic of Congo struggles to contain mpox amid vaccine delays, conflict and fragile healthcare.
India sees unusual monsoon patterns
THE 2024 southwest monsoon has, between June 1 and September 1, led to excess rainfall in western and southern states such as Gujarat, Maharashtra and Tamil Nadu, while others like Nagaland, Manipur and Punjab recorded a deficit.